Aurinia Pharmaceuticals to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Rhea-AI Summary

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced that its executive management will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 1:00 p.m. ET. Interested parties can access the audio webcast through the “Investors” section on Aurinia's website, with a replay available afterward. Aurinia specializes in biopharmaceuticals, notably launching LUPKYNIS™, the first FDA-approved oral therapy for adult patients with active lupus nephritis.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat at the (virtual) SVB Leerink 10^th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 1:00 p.m. ET.

In order to participate in the audio webcast, interested parties can access the live webcast under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

ABOUT AURINIA

Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company has introduced LUPKYNIS™ (voclosporin), the first FDA-approved oral therapy dedicated for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005041/en/

FAQ

What is the date and time of Aurinia Pharmaceuticals' participation in the SVB Leerink Conference?

Aurinia Pharmaceuticals will participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 1:00 p.m. ET.

How can I access the audio webcast of Aurinia Pharmaceuticals' fireside chat?

The audio webcast can be accessed under the 'News/Events' section on Aurinia's corporate website.

What is LUPKYNIS™ and why is it significant?

LUPKYNIS™ (voclosporin) is the first FDA-approved oral therapy specifically for adult patients with active lupus nephritis, addressing a high unmet medical need.

Where is Aurinia Pharmaceuticals headquartered?

Aurinia Pharmaceuticals is headquartered in Victoria, British Columbia.

What is the stock ticker for Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals trades under the stock ticker AUPH on NASDAQ.